ImaRx to Report Corporate Updates and 4Q07 Financial Results
The live webcast can be accessed through ImaRx's corporate website atwww.imarx.com and will be archived on the website for 14 days following theevent.
Interested parties may access the conference call by dialing (877) 407-4018 in the U.S. and Canada or (201) 689-8471 internationally. A telephonicreplay will be available through April 3, 2008 by dialing (877) 660-6853 inthe U.S. and Canada or (201) 612-7415 internationally (Account Number 3055 andConference ID 279436).
About ImaRx Therapeutics
ImaRx Therapeutics is a biopharmaceutical company commercializing anddeveloping therapies for vascular disorders. The Company's commercializationefforts are currently focused on its FDA approved product, urokinase, for thetreatment of acute massive pulmonary embolism. The Company's research anddevelopment efforts are focused on therapies for stroke and other vasculardisorders using its proprietary microbubble technology.
Cautionary Statement For The Purpose Of The "Safe Harbor" Provisions OfThe Private Securities Litigation Reform Act of 1995
Note: Statements made in this press release which are not historical innature constitute forward-looking statements for purposes of the safe harborprovided by the Private Securities Litigation Reform Act of 1995. Suchstatements include but are not limited those related to our efforts to growthe marketplace for urokinase, our intent to reduce our operating expensesassociated with our SonoLysis development and our belief that we will allowthe Company to explore additional therapeutic applications for the product.These statements are based on management's current expectations and beliefsand are subject to a number of factors and uncertainties that could causeactual results to differ materially from those described in the forward-looking statements. Such risks and uncertainties include but are not limitedto: sales of and demand for urokinase may decline, the FDA may not approve ourfuture requests for urokinase lot releases or approval of expanded uses ofurokinase beyond treatment of acute massive pulmonary emboli, we may not beable to complete definitive documentation with Microbix on the terms of ourletter of intent, Microbix may not be able to perfect the manufacturingprocess or to secure approval from the FDA to manufacture urokinase, we maynot be effective in our marketing efforts for urokinase, and we may not haveor be able to secure sufficient capital to fund our operations and thedevelopment and commercialization of our product candidates. All informationin this press release is as of January 30, 2008, and the Company undertakes noduty to update this information. A more complete description of these riskscan be found in the Company's filings with the Securities and ExchangeCommission.Contacts: The Ruth Group Sara Ephraim (investors) 646-536-7002 email@example.com Jason Rando (media) 646-536-7025 firstname.lastname@example.org
SOURCE ImaRx Therapeutics, Inc.
You May Also Like